Key result
Heart failure with high BNP and 30-day major bleeding after PCI were associated with a high risk of MACE compared to patients without either risk factor (HR 8.33; 95% CI 2.57-27.0).
Why the study?
Heart failure confers high bleeding risk after PCI and major bleeding increases cardiovascular risk, but whether HF severity and bleeding events are associated with MACE is unknown.
Does heart failure severity (high BNP) and 30-day major bleeding increase the risk of subsequent MACE in patients after percutaneous coronary intervention?
Cohort (n=7,160)
Yes
Does heart failure severity (high BNP) and 30-day major bleeding increase the risk of subsequent MACE in patients after percutaneous coronary intervention?
Hazard Ratio: 8.33 (95% CI 2.57–27)
Heart failure with elevated BNP and early major bleeding after PCI are associated with a substantially increased risk of subsequent major adverse cardiac events.
Background Heart failure (HF) is one of high bleeding risk after percutaneous coronary intervention (PCI). Furthermore, major bleeding events increase the risk of subsequent cardiovascular events. However, it is unknown whether HF severity and bleeding events are associated with major adverse cardiac events (MACE). Purpose The aim of this study was investigating the impact of HF severity or bleeding events on subsequent MACE. Methods Clinical Deep Data Accumulation System (CLIDAS), a multicenter database with 7 tertiary medical hospitals, was developed to collect data directly for patient characteristics, medications, laboratory test, physiological test, cardiac catheterization and PCI treatment in electronic medical records. This retrospective analysis included 7,160 patients with PCI between April 2014 and March 2020 and have completed 3-year follow-up. The patients were divided into two groups: HF with high BNP (HF-hBNP) (>100 pg/ml) (n=384) and non-HF-hBNP (HF with low BNP and non-HF) (n=6,776). Furthermore, both groups were re-classified into two groups according to presence of major bleeding events in 30 days: HF-hBNP with 30-day bleeding (n=14), without 30-day bleeding (n=370), non-HF-hBNP with 30-day bleeding (n=74) and without 30-day bleeding (n=6,702). Primary endpoint was defined as MACE. Results HF with high BNP was an independent risk factor of MACE (hazard ratio [HR], 2.21; 95% confidence interval [CI], 1.64-2.98) compared with non-HF. Among the HF-hBNP patients, MACE incidence tended to be increased by 30-day bleeding (p=0.075). In addition, among the non-HF-hBNP patients, the bleeding events increased the risk of MACE (p=0.003). The multivariable Cox regression model revealed that other three groups were associated with a high risk compared with non-HF-hBNP without 30-day bleeding group: non-HF-hBNP with 30-day bleeding (HR, 3.90; 95% CI, 1.59-9.54), HF-hBNP without 30-day bleeding (HR, 2.19; 95% CI, 1.56-3.07) and HF-hBNP with 30-day bleeding (HR, 8.33; 95% CI, 2.57-27.0). Conclusion The real-world database CLIDAS revealed that HF with high BNP and major bleeding events in 30 days might be associated with MACE. Those results suggest that management of HF and prevention of bleeding complication in early days after PCI could be important to prevent MACE.
No takes yet. Share an insight, caveat, or question.
Ikebe et al. (2023) conducted a cohort in Patients undergoing percutaneous coronary intervention (PCI) (n=7,160). Heart failure with high BNP (>100 pg/ml) and 30-day major bleeding vs. Non-HF with low BNP and no 30-day bleeding was evaluated on Major adverse cardiac events (MACE) (HR 8.33, 95% CI 2.57-27.0). Heart failure with high BNP and 30-day major bleeding after PCI were associated with a high risk of MACE compared to patients without either risk factor (HR 8.33; 95% CI 2.57-27.0).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: